At a Glance
Taiwan Resonant Waves Research Corp.(TRWR) was founded in 2010 in the capital of Taiwan – Taipei. Integrating innovative bioelectronic technology with medical devices, we are dedicated to helping patients with chronic diseases better manage health-related challenges.
There is unlimited promise in the application of bioelectronic medicine in the treatment of chronic diseases. Designed and developed by TRWR, Microcurrent Electrical Nerve Stimulation technology (MENS) is currently being used as a non-invasive, physical approach to treating and alleviating symptoms associated with diabetes mellitus.
Our vision is to lead the world in groundbreaking research and development in electroceutical technology as a means of enhancing quality of life, without the adverse side effects of conventional approaches.
We are committed to addressing the unmet medical needs of those suffering from chronic diseases by pursuing advancements in bioelectronic technology and delivering cost-effective healthcare solutions.
Our vision is to establish global presence as a Taiwanese brand through strategic collaborations and partnerships around the world. We strive to continually advance our core competences in Diabetes-MENS technology and expand our patent portfolio.
Innovation is no happenstance; it is the product of courage, perseverance, opportunity, and responsibility.
From Johannes Kepler to Sir Isaac Newton, the path to innovation is one that is filled with delight, toil, glory, and blessing.
February 2017 Acquired Taiwanese patent “System and method for reducing inflammation of tissue”
April 2017 Acquired Taiwanese patent “System and method for reliving hypertension”
April 2017 National Taiwan University Hospital and National Cheng Kung University Hospital, in collaboration with two other medical facilities, has begun a prospective, double-blind, randomized, placebo-controlled trial of Transcutaneous Electrical Nerve Stimulator (DW1330) to improve blood glucose control in patients with type 2 diabetes
May 2017 Fast Track for Clinical Trial Program has been approved by the Department of Industrial Technology of the Ministry of Economic Affairs (MOEA)
January 2016 Developed the medical device DW1330 for the relief of type 2 diabetes
March 2016 In collaboration with Taiwan Food and Drug Administration (TFDA) for assistance with medical device development
March 2016 Simultaneous acquisition of three Taiwanese patents: “Use of Bioresonant Waves on organisms as a method of control”, “System and method for autonomic nerve relaxation”, and “System and method for cardiovascular relief”
April 2016 Submitted a clinical trial application to TFDA for the registration of medical devices; the clinical trial at National Taiwan University Hospital (NTUH) is currently under review
April 2016 – Now Application for Chinese patent “System and method for relieving high blood sugar factor of diabetes”
June 2016 Acquired Taiwanese patent “Use of resonant frequency formula and control method for promoting immunity”
July 2016 US patent “Diabetes glucagon mitigation system and method with an electrical energy wave generator” was granted
July 2016 Acquired Taiwanese patent “Use of resonant frequency formula and method to decelerate the degeneration of the central nervous system as a result of Parkinson’s disease”
August 2016 Received review approval from Institutional Review Board of NTUH of new medical device clinical trial proposal: “Prospective, double-blind, randomized, placebo-controlled trial of Transcutaneous Electrical Nerve Stimulator (DW1330) to improve blood glucose control in patients with type 2 diabetes”
October 2016 Taiwanese patent “System and method for regulating water metabolism of cells” was granted
October 2016 Taiwanese patent “System and method for regulating cell metabolism” was granted
February 2015 Completed a pilot study for reducing cellular inflammation associated with periodontal disease (NTUH)
February 2015 Conducted an animal pilot study on the effects of Bioresonant Waves on Parkinson’s disease (Kaohsiung Medical University)
May 2015 Completed a pre-clinical animal study on the modulative effects of microcurrent electrical nerve stimulation in diabetic mice (National Taiwan Sport University)
June 2015 Established Academia Industry Alliance with National Chiao Tung University Department of Biological Science and Technology
June 2015 Conducted a proteomic analysis of animal models with type 2 diabetes (National Yang-Ming University)
October 2015 Completed an animal pilot study on the effects of Bioresonant Waves on Attention Deficit Hyperactivity Disorder (ADHD) (National Chung Cheng University)
November 2015 Conducted a transcriptome DNA microarray analysis of animal models with type 2 diabetes (Phalanx Biotech Group)
January 2014 – December 2015 Conducted a single-blind, randomized study at Saint Mary’s Hospital Luodong on the effects of “Dragon Waves Resonant Home Care Electronic Nerve Stimulator” (DW1330) on improving blood glucose control in patients with type 2 diabetes (sample size of 80)
April 2014 Acquired certification of medical electrical equipment – general requirements for basic safety and essential performance (IEC 60601-1:2005, IEC 60601-1-11:2010, IEC 60601-2-10:2012)
May 2014 Obtained the certification of medical electrical equipment: general requirements for basic safety and essential performance – collateral standard: electromagnetic disturbances – requirements and tests (IEC60601-1-2:2007)
September 2014 Acquired Taiwanese patent “Diabetes glucagon mitigation system and method with an electrical energy wave generator”
October 2014 Application for US patent “Diabetes glucagon mitigation system and method with an electrical energy wave generator”
January 2013 Our manufacturing partner Goldensunda Technology Co., Ltd. obtained the medical device manufacturing license (GMP)
January 2013 Completed a study on the effects of Bioresonant Waves on enhancing mitochondrial ATP production
March 2013 Launched “Dragon Waves Resonant Home Care Electronic Nerve Stimulator” (DW1330) and obtained medical device license no. 003997 with blood circulation, pain relief, and relaxation functions
June 2013 Completed a study on the effects of Bioresonant Waves on inhibiting cancer cell growth
July 2013 Completed a study on patients with type 2 diabetes from Luodong
Neng-Chun Diabetes Clinic
August 2012 Acquired pharmaceutical product license (no. 620117J595)
October 2012 Development of “Dragon Waves Resonant Home Care Electronic Nerve Stimulator” (DW1330) was completed
November 2012 Completed a physiological research report on blood circulation
December 2012 Our manufacturing partner Goldensunda Technology Co., Ltd. obtained the certification of Medical Devices-Quality Management Systems-Requirements for Regulatory Purposes (ISO 13485:2012)